NewsRoom Articles - Page 54 of 154 - PsychedelicNewsWire (PNW)

WednesdayJul 13, 2022 3:48 pm

States That Have Made Advancements Toward Legalizing Psychedelics

Interest in psychedelics has grown significantly as mainstream acceptance grows and research uncovers more of the benefits that these substances possess, including how they can be used to manage a range of mental health disorders. These positive advancements have even led some states to decriminalize these controlled substances, with other states set to legalize the substances in the near future. Let’s look at some of the states that may soon legalize psychedelics. Oregon In November 2020, the state of Oregon passed a measure that would establish legal psychedelic healing centers where individuals aged 21 and above could undergo psilocybin-assisted therapy.…

WednesdayJul 13, 2022 9:00 am

Homing Peptides: Silo Pharma Inc. (SILO) Targets ADRs

Silo’s partnership with UMB could yield therapeutics that limit side effects through precisely targeted delivery On February 3, 2022, Silo Pharma (OTCQB: SILO) extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). The ability to target inflamed tissue (while bypassing healthy organs) suggests joint-homing peptides could deliver therapeutics or fusion imaging nanoparticles to specific diseased tissues. Better imaging, lower radiation and precision, targeted dosing could enhance the therapeutic effect of current and future therapeutics and…

TuesdayJul 12, 2022 3:58 pm

DEA Sets Hearing Date Regarding Plan to Ban Several Psychedelics

In January, the Drug Enforcement Administration announced a proposed ban on five psychedelics: 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT. With the country going through what some have called a psychedelics renaissance, the agency received significant criticism for its proposed decision. As such, the DEA stated in a recent notice that it will be holding a hearing on Aug. 22, 2022, to listen to testimonies from individuals who were “adversely aggrieved or affected” by its proposed ban. The agency received plenty of backlash from researchers and advocates at the start of the year when it first proposed the ban. According to…

MondayJul 11, 2022 1:42 pm

Congressional Leaders Want Studies to be Conducted on Mental Health Benefits of Psychedelics

Initial research on psychedelics back in the 1950s and 1960s found that treatments involving psychedelic drugs could lead to positive mental health outcomes. However, the U.S. government criminalized psychedelics in the late 1960s. The substances remained illegal for decades until a few states began loosening their own psychedelic policies in recent years. With psychedelics seeing a resurgence in mainstream and scientific interest, Congressional leaders are calling for more research on the potential of psychedelic drugs to treat debilitating mental health conditions such as post-traumatic stress disorder (PTSD) and depression. For example, House Appropriations Committee leaders have included provisions for spending…

FridayJul 08, 2022 11:13 am

Study Suggests How Psychedelic Integration Can Be Measured

There has been increased interest in psychedelic treatments in recent years as initial studies have revealed that psychedelic drugs have the potential to alleviate certain mental health conditions. Psychedelic therapy is a relatively new field, but it has shown great promise in treating conditions such as mood disorders and post-traumatic stress disorder (PTSD). Now a study that was recently published in “Frontiers of Psychology” looks to give physicians a way to apply and measure psychedelic integration throughout the therapy process. Psychedelic integration refers to a process where a patient revisits their past traumatic experiences under the influence of psychedelics, pays…

ThursdayJul 07, 2022 12:59 pm

Federal Health Agencies Admit That Classification of Psychedelics Is Impeding Research

Several psychedelics are outlawed by federal law, with the United States classifying drugs such as psilocybin, LSD, MDMA, mescaline and peyote as Schedule I controlled substances with no accepted medical use. Even though a few states have loosened some of their psychedelic policies, federal law prohibits the production, sale and use of psychedelic drugs. According to two federal health agencies, federal prohibition has forced researchers to jump through numerous regulatory hoops and held back efforts to study the potential benefits and risks of psychedelic drugs. In a four-page letter sent as a response to Sen. Cory Booker’s and Sen. Brian…

WednesdayJul 06, 2022 2:42 pm

Archaeologists Believe Hidden Andean Passageways Were Most Likely Used During Psychedelic Rituals

In the past few years, archaeological studies have revealed that ancient people may have used recreational drugs in their rituals. According to archaeologists, ancient Andean civilizations may have used hidden passageways to take part in rituals that involved psychedelic drugs. Archaeologists on a dig in Peru discovered a network of hidden galleries and passageways deep inside an ancient temple complex called Chavin de Huántar, which is located in the Peruvian Andes. The archaeologists believe that this complex of passageways and chambers was used in religious rituals that may have involved psychedelic drugs. These hidden structures had been sealed off from…

TuesdayJul 05, 2022 2:03 pm

Canadian Company Seeks Permission to Produce Psychedelics Such as LSD, MDMA

A Canadian company based in Vancouver, Canada, is seeking permission from regulators to produce psychedelics such as LSD and MDMA at its British Columbia facility. Psychedelics have been seeing a resurgence in popularity in Canada, with the country’s national health policy agency moving to approve the restricted use of psychedelics for therapy early this year. Opitmi Health Corporation, a company that develops natural mushroom formulations, has asked federal regulators to allow it to manufacture synthetic psychedelic drugs at its facility in British Columbia. The Vancouver-based company has requested a controlled substances dealers license that would allow it to synthesize psychedelic…

FridayJul 01, 2022 11:11 am

Study Finds That DMT May Be Used to Effectively Treat Depression

Anyone who has used DMT (N, N-dimethyltryptamine) knows that it is a powerful hallucinogen that can induce immersive hallucinations in only a few minutes. The drug’s effects are similar to those of other psychedelics, including psilocybin mushrooms and LSD. Now that psychedelics are seeing a resurgence in popularity, researchers have been interested in how these drugs can impact mental health. According to a new study published in the “Nature” journal, DMT may have the potential to treat depression. The researchers’ objective was to see whether administering DMT would have any effect on patients with depressive symptoms. Researchers discovered that patients…

ThursdayJun 30, 2022 2:00 pm

Appeal Board Upholds Compass Pathways’ Patent on Synthetic Psilocybin Formulation

A psychedelics company recently scored a major win after the Patent Trial and Appeal Board (PTAB) upheld a novel psychedelic patent that was under challenge. Compass Pathways PLC (NASDAQ: CMPS), a mental healthcare company based in the United Kingdom, synthesized and patented a type of psilocybin called Comp 360. In late 2021, a nonprofit called Freedom to Operate issued a legal challenge against the patents, arguing that Comp 360, which is also known as Polymorph A, was not a new and unique invention. The nonprofit stated that the synthetic psilocybin existed in the public domain and was not a novel…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000